论文部分内容阅读
目的： 评估经瘤体供血动脉灌注化疗药物治疗肺癌合并上腔静脉综合症（ＳＶＣＳ） 的疗效，并与静脉全身化疗效果进行比较。材料与方法： 肺癌合并ＳＶＣＳ 患者２８ 例，研究组１４ 例行动脉灌注化疗，对照组１４ 例行静脉全身化疗，比较两组的肿瘤退缩率及临床症状改善率。结果： 治疗前后ＫＰＳ 平均分差研究组增加１２ ．９ ，对照组增加１ ．４ 。胸片评估近期有效率，研究组为２９ ％ ，对照组为０ ％ ，经卡方检验，两组疗效差异显著（ Ｐ＜ ０ ．０５） 。结论： 动脉灌注化疗治疗肺癌并发的ＳＶＣＳ 临床有效率及显效速度均优于静脉全身化疗。
OBJECTIVE: To evaluate the efficacy of intratumoral arterial infusion chemotherapy for the treatment of lung cancer associated with superior vena cava syndrome (SVCS) and to compare the efficacy of intravenous systemic chemotherapy. Materials and Methods: Twenty-eight patients with lung cancer and SVCS were involved. In the study group, 14 patients received arterial infusion chemotherapy. In the control group, 14 patients received intravenous systemic chemotherapy. Tumor retraction rate and clinical symptom improvement rate were compared between the two groups. Results: The KPS mean score difference between the study group and the treatment group increased by 12%. 9, the control group increased by 1. 4. Chest radiograph assessment of recent effective rate, the study group was 29%, the control group was 0%, the chi-square test, the difference was significant between the two groups (P < 0. 05). Conclusion: The clinical efficacy and effective rate of arterial infusion chemotherapy for the treatment of lung cancer complicated with SVCS are superior to those of intravenous systemic chemotherapy.